ArticleCureus2025
Durable Disease Control Following Multimodal Therapy in Prostate Cancer With a Massive Pelvic Lymph Node Metastasis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer with a massive pelvic lymph node metastasis is uncommon, and its optimal management remains uncertain. We describe the case of a 69-year-old man with a cT3aN1M0 prostate cancer and a 10 cm (175 cm³) pelvic lymph node metastasis. He received multimodal therapy consisting of androgen deprivation therapy (ADT), seven cycles of docetaxel, and external beam radiotherapy. This approach led to marked regression of the nodal disease and sustained suppression of prostate-specific antigen (PSA) to <0.01 ng/mL for longer than 14 months without additional systemic treatment. Although the therapeutic strategy deviated from current guideline-based recommendations, the case highlights that combining systemic therapy with radiotherapy can achieve durable disease control in selected patients with locally advanced prostate cancer and massive lymph node involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.